Biotech entity
Every one of those 1 sits in a single category, clinical-trial. Of the tracked stories, 1 of 1 also mention BPL-003, the most common co-covered peer. AtaiBeckley appears in 1 tracked Biotech story from March 8, 2026. The tracked stories average 2 original sources each.
Last mentioned: Mar 8, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, clinical-trial. Of the tracked stories, 1 of 1 also mention BPL-003, the most common co-covered peer. AtaiBeckley appears in 1 tracked Biotech story from March 8, 2026. The tracked stories average 2 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 10 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering AtaiBeckley. Shared-story counts are live from our verified record — not editorial picks.
Enrollment Milestone
Estimated completion of patient enrollment for the global Phase 3 study.
Phase 3 Launch Window
Expected start of the pivotal Phase 3 trial for Treatment-Resistant Depression.
Earnings & Timeline Release
Company announces 2025 results and sets Q2 2026 for BPL-003 Phase 3 launch.
FY 2025 Close
End of the fiscal year reporting period for AtaiBeckley.
AtaiBeckley (ATAI) has confirmed the Q2 2026 launch of its Phase 3 program for BPL-003, an intranasal 5-MeO-DMT formulation for Treatment-Resistant Depression. The announcement follows the release of 2025 financial results that show a robust cash position capable of funding pivotal late-stage clinical development.
AtaiBeckley is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
